Loading data for TCRX — first visit, this takes a few seconds.

알림

TScan Therapeutics Inc. (TCRX)

NasdaqGM: TCRX · 실시간 가격 · USD

0.78

-0.01 (-1.27%)

종가 기준: Aug 26, 2026, 8:00 PM

0.78

+0.00%

애프터마켓: 4:04 PM

주가와 핵심 숫자, 최신 뉴스를 한 곳에 모았습니다.

-1.27% (1D)

데이터 없음

매수호가	0.54
시가총액	52.69M
매출 (ttm)	7.11M
순이익 (ttm)	-117.71M
	1.07
	-0.9
	n/a
	-0.83
P/B (ttm)	0.48
P/S (ttm)	7.14
실적 발표일	Nov 12, 2025

매도호가	0.97
거래량	68,332
평균 거래량 (20일)	599,171
시가	0.78
전일 종가	0.79
일중 범위	0.77 - 0.79
52주 범위	0.72 - 2.57
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

TCRX 소개

TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Jul 16, 2021

직원 수 138

상장 거래소 NasdaqGM

티커 TCRX

웹사이트 https://www.tscan.com

전체 기업 정보

재무 실적

2025년 TScan Therapeutics의 매출은 10.32M로, 전년 2.82M 대비 266.65% 증가했습니다. 순이익은 -129.77M로, 1.78% 증가했습니다.

재무제표

어닝 서프라이즈

TScan Therapeutics가 Aug 12, 2026에 분기 실적을 발표했습니다:

매출 $982K 예상치 하회 $0, 및 -54.77% 전년 대비 감소.
EPS -0.23 예상치 하회 -0.03, 및 17.86% 전년 대비 성장.

다음 실적 발표

TScan Therapeutics Inc.의 실적 발표 예정일은 Nov 12, 2025, 장 시작 전입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

2시간 전 · Simply Wall St.

Why Is Amgen (AMGN) Ending Its Crohn's Disease Research Partnership?

Amgen (NasdaqGS:AMGN) has elected to terminate its research collaboration and license agreement with TScan Therapeutics focused on Crohn's disease target discovery. The decision ends Amgen's exclusive...

2주 전 · Zacks

TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Misses Revenue Estimates

TScan Therapeutics (TCRX) delivered earnings and revenue surprises of +20.69% and -61.78%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

2주 전 · Zacks

Prime Medicine, Inc. (PRME) Reports Q2 Loss, Misses Revenue Estimates

Prime Medicine, Inc. (PRME) delivered earnings and revenue surprises of 0.00% and -73.76%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

3주 전 · Pharmaceutical Technology

Cell and gene therapy manufacturers turn to specialist automation partners

These partnerships suggest that automation is becoming a practical priority for the cell and gene therapy industry.

2개월 전 · Insider Monkey

TScan Therapeutics, Inc. (TCRX) Reports Q1 2026 Results With Improved Net Loss

We recently compiled a list of the 10 Popular Penny Stocks on Robinhood to Watch in 2026. TScan Therapeutics, Inc. (NASDAQ:TCRX) is one of the most popular penny stocks. TheFly reported on May 6 that ...

2 페이지 중 1

TScan Therapeutics Inc. (TCRX)